Loading...
Docoh

Candel Therapeutics (CADL)

Candel is a late clinical stage biopharmaceutical company focused on helping patients fight cancer with oncolytic viral immunotherapies. Candel’s engineered viruses are designed to induce immunogenic cell death through direct viral-mediated cytotoxicity in cancer cells, thus releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection. Candel has established two oncolytic viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs. CAN-2409 is the lead product candidate from the adenovirus platform, and CAN-3110 is the lead product candidate from the HSV platform.

Company profile

Ticker
CADL
Exchange
Employees
Incorporated
Location
Fiscal year end
SEC CIK
Subsidiaries
Candel Therapeutics Securities Corporation ...
IRS number
522214851

CADL stock data

Calendar

5 Aug 22
16 Aug 22
31 Dec 22
Quarter (USD) Jun 22 Mar 22 Dec 21 Sep 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 87.05M 87.05M 87.05M 87.05M 87.05M 87.05M
Cash burn (monthly) 2.57M (no burn) 2.92M 2.79M 1.66M 1.16M
Cash used (since last report) 4.03M n/a 4.58M 4.38M 2.6M 1.83M
Cash remaining 83.02M n/a 82.47M 82.67M 84.45M 85.22M
Runway (months of cash) 32.3 n/a 28.3 29.6 51.0 73.2

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
8 Aug 22 Gaeta Renee Stock Option Common Stock Grant Acquire A No No 3.38 28,480 96.26K 28,480
8 Aug 22 Gary J. Nabel Stock Option Common Stock Grant Acquire A No No 3.38 28,480 96.26K 28,480
8 Aug 22 Joseph C Papa Stock Option Common Stock Grant Acquire A No No 3.38 28,480 96.26K 28,480
28.9% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 24 21 +14.3%
Opened positions 5 11 -54.5%
Closed positions 2 2
Increased positions 6 5 +20.0%
Reduced positions 6 1 +500.0%
13F shares Current Prev Q Change
Total value 33.97M 54.36M -37.5%
Total shares 8.36M 8.64M -3.2%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners Shares Value Change
FMR 1.97M $10.04M -12.8%
Northpond Ventures 1.94M $9.85M 0.0%
Northpond Ventures 1.69M $0 0.0%
BEN Franklin Resources 1.13M $5.73M 0.0%
Sands Capital Ventures 811.74K $4.13M 0.0%
Vanguard 407.16K $2.07M -2.0%
BLK Blackrock 132.32K $674K +15.5%
Geode Capital Management 75.22K $382K +29.1%
Bridgeway Capital Management 75K $382K NEW
683 Capital Management 40.93K $208K 0.0%
Largest transactions Shares Bought/sold Change
FMR 1.97M -290.62K -12.8%
Woodline Partners 0 -100K EXIT
Bridgeway Capital Management 75K +75K NEW
BLK Blackrock 132.32K +17.71K +15.5%
Geode Capital Management 75.22K +16.93K +29.1%
Millennium Management 0 -13.11K EXIT
Kestra Advisory Services 12.5K +12.5K NEW
Empirical Asset Management 12K +12K NEW
Vanguard 407.16K -8.2K -2.0%
UBS UBS Group AG - Registered Shares 2K -2.45K -55.0%

Financial report summary

?

Content analysis

?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. senior Avg
New words: aforementioned, appeal, ballot, blood, Canadian, CDPA, Colorado, combat, Connecticut, constitutionality, CPA, CPDA, CPRA, CTDPA, depth, dismissed, empyema, enLIGHTEN, excessive, gcomprehensive, glioblastoma, globe, gouging, governor, Indian, instructed, Lamont, lawsuit, Maryland, median, methylated, MGMT, Modernization, moratorium, motion, nivolumab, nomenclature, oral, paired, pyrexia, radiotherapy, randomized, ratio, regime, regression, sixty, stay, suggesting, temozolomide, UCPA, UK, unnecessary, Utah, variation, Virginia, waiver, whichever, wproduct
Removed: ALT, Blueprint, Brexit, burden, calling, constitutional, creatinine, displayed, elevation, feedback, incentivize, leave, left, penalty, pocket, presidential, proposal, recruited, repealed, revising, revision, soliciting, step, synthetic, Trump, undergoing
Proxies
No filings